Bispecific Antibodies Targeting Distinct Regions of the Spike Protein Potently Neutralize SARS-CoV-2 Variants of Concern
Hyeseon Cho,Kristina Kay Gonzales-Wartz,Deli Huang,Meng Yuan,Mary Peterson,Janie Liang,Nathan Beutler,Jonathan L. Torres,Yu Cong,Elena Postnikova,Sandhya Bangaru,Chloe Adrienna Talana,Wei Shi,Eun Sung Yang,Yi Zhang,Kwanyee Leung,Lingshu Wang,Linghang Peng,Jeff Skinner,Shanping Li,Nicholas C. Wu,Hejun Liu,Cherrelle Dacon,Thomas Moyer,Melanie Cohen,Ming Zhao,Frances Eun-Hyung Lee,Rona S. Weinberg,Iyadh Douagi,Robin Gross,Connie Schmaljohn,Amarendra Pegu,John R. Mascola,Michael Holbrook,David Nemazee,Thomas F. Rogers,Andrew B. Ward,Ian A. Wilson,Peter D. Crompton,Joshua Tan
DOI: https://doi.org/10.1126/scitranslmed.abj5413
IF: 17.1
2021-01-01
Science Translational Medicine
Abstract:The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern threatens the efficacy of existing vaccines and therapeutic antibodies and underscores the need for additional antibody-based tools that potently neutralize variants by targeting multiple sites of the spike protein. We isolated 216 monoclonal antibodies targeting SARS-CoV-2 from plasmablasts and memory B cells collected from patients with coronavirus disease 2019. The three most potent antibodies targeted distinct regions of the receptor binding domain (RBD), and all three neutralized the SARS-CoV-2 Alpha and Beta variants. The crystal structure of the most potent antibody, CV503, revealed that it binds to the ridge region of SARS-CoV-2 RBD, competes with the angiotensin-converting enzyme 2 receptor, and has limited contact with key variant residues K417, E484, and N501. We designed bispecific antibodies by combining nonoverlapping specificities and identified five bispecific antibodies that inhibit SARS-CoV-2 infection at concentrations of less than 1 ng/ml. Through a distinct mode of action, three bispecific antibodies cross-linked adjacent spike proteins using dual N-terminal domain–RBD specificities. One bispecific antibody was greater than 100-fold more potent than a cocktail of its parent monoclonals in vitro and prevented clinical disease in a hamster model at a dose of 2.5 mg/kg. Two bispecific antibodies in our panel comparably neutralized the Alpha, Beta, Gamma, and Delta variants and wild-type virus. Furthermore, a bispecific antibody that neutralized the Beta variant protected hamsters against SARS-CoV-2 expressing the E484K mutation. Thus, bispecific antibodies represent a promising next-generation countermeasure against SARS-CoV-2 variants of concern.